The trial will evaluate the efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The data is expected in early 2022
Nipah virus (NiV) is an emerging zoonotic disease that causes severe disease in humans. Signs and symptoms range from asymptomatic to acute respiratory infection and fatal encephalitis
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
In comparison to traditional open-heart surgery, which involves opening up the chest by splitting the breastbone, da Vinci Xi's innovative technology allows for complex cardiovascular surgeries to be performed through smaller incisions and precise motion control
At present 18 per cent of the local pharmaceutical market is under government's price control
This is the third acquisition by Healthium this year apart from AbGel business in India and VitalCare in the UK
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
Subscribe To Our Newsletter & Stay Updated
